Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waverley buys two in the UK

Executive Summary

Canada’s Waverley Pharma has acquired two UK oncology generics, capecitabine and temozolomide, from Reliance Life Sciences. “The products were developed by Reliance Life Sciences and the binding contracts with the UK National Health Service (NHS) for the supply of these products are being transferred to Waverley Pharma,” the firm noted.

You may also be interested in...



Waverley Lists In Frankfurt

Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.

Waverley Expands UK Cancer Portfolio

Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.

US House Co-signs Banking For Hemp Industry

House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.

Topics

UsernamePublicRestriction

Register

GB000866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel